Philadelphia, PA (July 21, 2020) – Oncoceutics, a clinical-stage drug discovery and development company, announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to Oncoceutics’ investigational cancer drug ONC201 for the treatment of “H3 K27M-mutant glioma”. The Rare Pediatric Disease Priority Review Voucher program, which was created as
Philadelphia, PA (July 22, 2020) – Oncoceutics, a clinical-stage drug discovery and development company, commemorates GBM Awareness Day this July and expresses its support for all those affected by this devastating form of brain cancer. Glioblastoma (GBM) is the most common type of malignant brain tumor among adults and is typically fatal. The two-year survival
Philadelphia, PA (June 8, 2020) – Oncoceutics announced today a Brown University award of $3.4 million that will be used to support a group of research teams for preclinical research, IND-enabling studies and a first-in-human clinical trial for Oncoceutics’ imipridone ONC212. As part of this award, Oncoceutics has received a $1M subaward to complete the
Philadelphia, PA (May 28, 2020) – Oncoceutics, Inc. announced that it and its collaborators will present several abstracts at the virtual 2020 Annual Meeting of the American Society of Clinical Oncology (ASCO) from Friday, May 29th to Tuesday, June 2nd that highlight the clinical safety and efficacy of ONC201 across a number of clinical trials,
Business Development